Talis Biomedical Corporation (TLIS) Tops Q2 EPS by 131c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall St futures jump as Democrats sweep midterms
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts TLIS Hot Sheet
Join SI Premium – FREE
Talis Biomedical Corporation (NASDAQ: TLIS) reported Q2 EPS of ($8.27), $1.31 better than the analyst estimate of ($9.58). Revenue for the quarter came in at $580 thousand versus the consensus estimate of $102.5 thousand.
For earnings history and earnings-related data on Talis Biomedical Corporation (TLIS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Datadog stock tumbles 19% despite earnings beat
- SmartRent (SMRT) Reports In-Line Q3 EPS
- Peabody Energy (BTU) Misses Q3 EPS by 28c
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
